InsidersTradesSigma
Track the Zymeworks BC Inc. stock price and the full insider trade history of the company, a publicly traded company based in United States. Shares are listed on US US, under the oversight of SEC (Form 4). Market capitalisation: €1.9bn. The latest transaction was filed on 14 November 2022 (Levée d'options). Among the most active insiders: Josephson Neil. The full history is free.
Analysts rate Zymeworks BC Inc. Strong Buy (bullish), based on 13 analysts. Average price target: US$40.15.
This score ranks the purchase within its own market. No market currently meets the historical allocation criteria, so signals remain watch-only. Not investment advice.
Transparent value + quality ranking, distinct from the insider signal.
Fundamental view, insider signal, bull and bear case, synthesis.
AI-generated analysis. Opinion, not investment advice. Not backtested. Built from public filings and financials. No price target, no buy or sell recommendation.
1 of 1 declaration
Zymeworks BC Inc. is a biopharmaceutical company focused on developing protein-based therapies for the treatment of cancer and other diseases. It is listed on NASDAQ under the ticker symbol ZYME.